of Screening Compounds
Drug Discovery Services
Pharma News, 2019
Common early sign of cardiovascular disease also may indicate cancer risk, study finds
A Mayo Clinic-led study involving 488 cardiac patients whose cases were followed for up to 12 years finds that microvascular endothelial dysfunction, a common early sign of cardiovascular disease, is ...
Liver damage from drinking may one day be REVERSIBLE: Scientists are developing a drug to undo tissue scarring in lung and liver disease
Doctors may some day be able to reverse the damage that years of heavy drinking does to the liver, a new study suggests.
With 2 Failed Trials, Cyclerion Announces Plans to Cut 30 Out of 135 Jobs
Cyclerion Therapeutics had a tough day, announcing the failure of two separate clinical trials for the same drug on the same day.
Gilead, Glympse Bio to explore biomarker use in NASH
Gilead has announced a new strategic collaboration with Glympse, in order to explore the use of biomarker technology in nonalcoholic steatohepatitis (NASH) clinical development.
MorphoSys, Novartis, Galapagos abandon experimental MOR106
MorphoSys, Novartis and Galapagos have announced the premature end of the clinical development program of MOR106 in atopic dermatitis, citing “low probability to meet main goal of study.
AstraZeneca divests rights to Seroquel and Seroquel XR in Europe and Russia
AstraZeneca has agreed the sale and licence of the commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in Europ...
Mirati drug shrinks tumors in some cancer patients in early-stage trial
An experimental drug from Mirati Therapeutics Inc that targets a specific genetic mutation significantly reduced tumor size in 40% of patients with advanced lung and colorectal cancer so far evalu...
Allergan settles Alzheimer's therapy lawsuit for $750 million
(Reuters) - Allergan Plc would pay $750 million to settle a class action lawsuit from a group of direct purchasers of Alzheimer’s disease therapy Namenda, the drugmaker said, in a resolution...
Schizophrenia biomarker (hydrogen sulfide) in human hair
Working with model mice, post-mortem human brains, and people with schizophrenia, researchers at the RIKEN Center for Brain Science in Japan have discovered that a subtype of schizophrenia is related ...
Cannabis not proven in mental health: study
Australian researchers have found little evidence that medicinal cannabis can relieve mental illnesses such as anxiety, depression and psychosis.
AVROBIO Receives Orphan-Drug Designation from the U.S. FDA for AVR‑RD‑02 for the Treatment of Gaucher Disease
FDA APPROVES BOTOX® (ONABOTULINUMTOXINA) FOR PEDIATRIC PATIENTS WITH LOWER LIMB SPASTICITY, EXCLUDING SPASTICITY CAUSED BY CEREBRAL PALSY
Go to cart
You will be able to Pay Online or Request a Quote
Catalog of Screening Compounds
Focused and Target Libraries
Active Reference Sets
Drug Discovery Services
In silico Drug Design (CADD)
Toxicology and Safety
Chemistry, Manufacturing and Controls
News & Media
Trends in discovery compounds